Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and highdensity lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of dyslipidemia

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by drug class

Statins

Cholesterol absorption inhibitors

Dyslipidemia injectables

Others

PART 09: Geographical segmentation

Dyslipidemia drugs market in Americas

Dyslipidemia drugs market in EMEA

Dyslipidemia drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

Market drivers

Impact of drivers on key customer segments

Market challenges

Impact of challenges on key customer segments

PART 12: Market trends

Increasing use of statins

Combination therapies

Increased uptake of OTC drugs

PART 13: Vendor landscape

Competitive scenario

PART 14: Key vendor analysis

Aegerion Pharmaceuticals

AstraZeneca

Merck

Pfizer

Sanofi

Other prominent vendors

PART 15: Appendix

List of abbreviations

PART 16: Explore Technavio